Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
103
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
103
01:30Bipolar Disorder
36
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
36
01:30Electroconvulsive Therapy
18
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
18
01:23Antidepressant Drugs: MAOIs and Other Agents
162
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
162
01:11Blinding
2.3K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.3K
01:18Depression: Overview
191
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
191
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.
EClinicalMedicine·2026
Same author
Lithium versus valproate in bipolar disorder: Associations with dementia, mortality, suicide attempt, and end-stage renal disease in adults aged 45 years and older - a propensity score-matched retrospective cohort study.
Psychiatry research·2026
Same author
Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation.
Alzheimer's research & therapy·2026
Same author
Risks and Familial Coaggregation of Autism Spectrum Disorder Among First-Degree Relatives of Individuals With Colorectal Cancer.
Psychiatry investigation·2026
Same author
Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia].
Psychiatry and clinical neurosciences·2026
Same author
Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance.
Journal of affective disorders·2026
Same journal
Interventions to support recovery of people with psychosis in low-income and middle-income countries: a systematic review.
The lancet. Psychiatry·2026
Same journal
Psychosis, human rights, and legal frameworks: global perspectives, with a focus on low-income and middle-income countries.
The lancet. Psychiatry·2026
Same journal
My voice's vocabulary: how antipsychotics change the way my voice speaks.
The lancet. Psychiatry·2026
Same journal
Brain lithium temporospatial kinetics in bipolar disorder: a repeated-measures <sup>7</sup>Li MRI study of dosing regimens in Germany.
The lancet. Psychiatry·2026
Related Experiment Video
Updated: May 11, 2025
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
13.8K
Bipolar depression management needs randomised controlled trial evidence
Chien Cheng1, Tien-Wei Hsu2, Yu-Chen Kao1
1Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan 112.
The Lancet. Psychiatry
|April 17, 2025
Summary
No abstract available in PubMed .
